Rituximab in the treatment of systemic sclerosis–related interstitial lung disease: a systematic review and meta-analysis

2020101 citationsReview

Authors

Rudra Prosad Goswami · All India Institute of Medical Sciences

Animesh Ray · All India Institute of Medical Sciences

Moumita Chatterjee · Aliah University

Arindam Mukherjee · Tata Medical Center

Geetabali Sircar · Institute of Post Graduate Medical Education and Research

Parasar Ghosh · Institute of Post Graduate Medical Education and Research

Abstract

Treatment with RTX in SSc-ILD was associated with a significant improvement of both FVC and DLCO during the first year of treatment. RTX use was associated with lower infectious adverse events.

Topics & Keywords

Systemic Sclerosis and Related Diseases Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Inflammatory Myopathies and Dermatomyositis

UN Sustainable Development Goals

Clean water and sanitation

Publication Details

Published in: Lara D. Veeken

Volume 60, Issue 2, pp. 557-567

DOI: 10.1093/rheumatology/keaa550

Field-Weighted Citation Impact: 10.29

Command Palette